Key analyses focus on treatment outcomes
among RA patients with a traditionally poor prognosis
ORENCIA® (abatacept)
continuing research underscores Bristol-Myers Squibb’s commitment
to advancing the science of modulating the body’s immune
response to treat disease
Bristol-Myers Squibb Company (NYSE:BMY) today confirmed that 23
abstracts related to ORENCIA® (abatacept), including new data on
the role of biomarkers and MRI in RA patient identification and
treatment, will be presented at the Annual European Congress of
Rheumatology (EULAR 2017), June 14-17 in Madrid, Spain. The Company
also will share first-in-human data from BMS-986165, an
investigational TYK2 inhibitor.
Bristol-Myers Squibb has played a leading role for more than two
decades in discovering and developing medicines designed to help
modulate the body’s immune response to treat disease. The abstracts
from Bristol-Myers Squibb accepted for EULAR 2017 include three
practice-informing analyses pertaining to ORENCIA treatment
responses in patients with highly active, progressive rheumatoid
arthritis (RA), who traditionally have a poor prognosis. 1-3
- A post hoc analysis of the phase 3
AGREE* clinical trial showing that among patients with early,
erosive RA, treatment with ORENCIA + MTX (vs. MTX alone) resulted
in higher seroconversion rates.2 Seroconversion refers to the RA
autoantibodies ACPA and RF – anti-citrullinated protein antibodies
and rheumatoid factor – falling to undetectable levels among
patients who entered the trial with measurable (seropositive)
levels.2 ACPA and RF are biomarkers associated with poor prognosis
in RA.2 The full data analysis will be featured in a poster tour on
Friday, June 16, from 11:45 – 13:30 CET.
- A post hoc analysis of the phase 3b
AVERT** study (MTX versus Orencia+MTX) evaluating the proportion of
patients achieving remission at 12 months as measured by baseline
MRI-detected inflammation status.3 The analysis explored the
response of patients with higher inflammation levels at baseline –
as measured by MRI – versus patients with lower baseline levels.3
The full data analysis will be featured in an oral presentation on
Friday, June 16, at 10:30 CET.
- A post hoc analysis of the phase 3b
AMPLE*** study that investigated the efficacy of ORENCIA+MTX versus
the TNF inhibitor adalimumab+MTX in patients with seropositive,
erosive early RA.1 The analysis looked at differences in treatment
effect between the two regimens among patients with seropositive,
erosive early RA. The full data analysis will be featured in a
poster tour on Saturday, June 17, from 10:15 – 12:00 CET.
“The research Bristol-Myers Squibb is presenting at EULAR 2017
shows our commitment to advancing scientific understanding of how
biomarkers and tools, such as MRI, can be used to guide patient
selection and treatment in highly active, progressive rheumatoid
arthritis,” said Brian J. Gavin, Vice President, ORENCIA
Development Lead at Bristol-Myers Squibb. “Importantly, the
research also yields critical insights into the role of modulating
the body’s immune system in rheumatoid arthritis and potentially
other autoimmune conditions where we are committed to making a
meaningful, positive impact on patients’ lives.”
In RA, the body’s immune system mistakenly attacks the joints.4
The costimulation blockade of ORENCIA prevents T-cell activation
and the resulting cascade of events that contribute to joint
destruction.
The full listing of abstracts Bristol-Myers Squibb will present
at EULAR 2017, including data and analyses in rheumatoid arthritis,
polyarticular juvenile idiopathic arthritis and psoriatic
arthritis, follows. Complete abstracts can be accessed online
here.
Abstract Title
Presentation Date and Time Oral Presentations OP0284:
Evaluation of the Impact of Baseline Friday, June 16
Levels of MRI-Detected Inflammation on Treatment 10:30 CET Response
in Early, Seropositive, MTX-Naïve RA: Data from the AVERT Trial
OP0223: Abatacept in the Treatment of Active
Friday, June 16 Psoriatic Arthritis: 1-Year Results from a Phase
11:30 CET III Study OP0058: Improvement in
Patient-Reported Outcomes Wednesday, June 14 in Patients with
Polyarticular-Course Juvenile 17:25 CET Idiopathic Arthritis and
Inadequate Response to Biologic or Non-Biologic Disease-Modifying
Antirheumatic Drugs Treated with SC Abatacept
OP0101: Risk of Opportunistic Infections in Thursday, June 15
Patients with Rheumatoid Arthritis Initiating 10:50 CET Abatacept:
Analysis of all Available Clinical Trial Data
Poster Tours FRI0219: Association Between
Seroconversion Friday, June 16 Status and Clinical Outcomes
Following Treatment 11:45 – 13:30 CET with Abatacept in Combination
with Methotrexate Compared with Methotrexate Alone in Patients with
Early Rheumatoid Arthritis and Poor Prognostic Indicators
SAT0041: Efficacy of Abatacept versus Adalimumab
Saturday, June 17 in Patients with Seropositive, Erosive Early RA:
10:15 – 12:00 CET Analysis of a Randomized Controlled Clinical
Trial (AMPLE) SAT0177: Safety Events are
Similar with Abatacept Saturday, June 17 Versus Placebo Treatment
in RA: Results from 10:15 – 12:00 CET Integrated Data Analysis from
Nine Clinical Trials FRI0129: Comparative
Safety of Biologic DMARD Friday, June 16 Initiation in RA: A
Population-Based 11:45 – 13:30 CET Observational Study of
Malignancy Risk SAT0226: A First-in-Human,
Study of BMS-986165, a Saturday, June 17 Selective, Potent,
Allosteric Small Molecule 10:15 – 12:00 CET Inhibitor of Tyrosine
Kinase 2
Poster Presentations
FRI0245: Abatacept Retention Rates and Prognostic Friday, June 16
Factors of Retention in Patients with Rheumatoid 11:45 – 13:30 CET
Arthritis: 2-Year Results from the Real-world ACTION Study
THU0104: Both MRI and HAQ-DI Can Predict Relapses
Thursday, June 15 Following all Treatment Withdrawal in MTX-Naïve
11:45 – 13:30 CET Patients with RA in Remission after 12 Months of
Abatacept Therapy in the AVERT Trial
THU0725-HPR: Cost Effectiveness Analysis of Thursday, June 15
Abatacept Compared with TNF Inhibitors in 11:45 – 13:30 CET
Patients who are Positive for Anti-Citrullinated Protein Antibodies
Based on Results from an Observational Trial
FRI0232: Treatment Effects of Abatacept and Anti- Friday, June 16
TNF in Patients with RA with Poor Prognostic 11:45 – 13:30 CET
Factors: Data from Community Rheumatology Clinics
SAT0188: First-Line Treatment Patterns of Saturday, June 17
Patients with Rheumatoid Arthritis who are Anti- 10:15 – 12:00 CET
Cyclic Citrullinated Peptide Antibody Positive Versus Negative
FRI0223: Anti-CCP is an Independent Predictor
of Friday, June 16 12-Month EULAR Response in Patients with RA
11:45 – 13:30 CET treated with Abatacept
THU0626: Cost-Effectiveness of Early Treatment of Thursday, June 15
ACPA Positive Rheumatoid Arthritis Patients with 11:45 – 13:30 CET
Abatacept THU0089: M-DAS28, DAS28 (CRP) and
RAPID3 Scores Thursday, June 15 at Baseline are Good Predictors of
Radiographic 11:45 – 13:30 CET Disease Progress at 1 and 2 Years:
Data from the AMPLE Trial SAT0197: Treatment
Outcomes with Anti-TNF and Saturday, June 17 Non-Anti-TNF
Disease-Modifying Therapy by 10:15 – 12:00 CET Baseline Body Mass
Index FRI0230: Retention Rates of TNF
Inhibitors and Friday, June 16 Abatacept Used as a First Biologic
DMARD in the 11:45 – 13:30 CET Treatment of Rheumatoid Arthritis: 8
Years of Experience from the RHUMADATA® Registry
SAT0468: Presence of Poor Prognostic Factors May Saturday,
June 17 Predict Response to Abatacept in Patients with 10:15 –
12:00 CET Active Psoriatic Arthritis: Results from a Post Hoc
Analysis from a Phase III Study FRI0520:
Improved Patient-Reported Outcomes in Friday, June 16 Psoriatic
Arthritis Patients Treated with 11:45 – 13:30 CET Abatacept:
Results from a Phase III Trial FRI0499:
Real-World Study on the Patterns and Friday, June 16 Cost of
Treatment Failure in Patients with 11:45 – 13:30 CET Psoriatic
Arthritis Using U.S. Claims Data THU0534:
Baseline Characteristics and Descriptive Thursday, June 15 Safety
Data of Intravenous Abatacept-Treated 11:45 – 13:30 CET Patients
with Juvenile Idiopathic Arthritis in a U.S. Healthcare Claims
Database FRI0106: Results of a Systematic
Literature Friday, June 16 Review of Prognostic Factors in
Rheumatoid 11:45 – 13:30 CET Arthritis as a Basis for a Prospective
Rheumatologists Survey
About Rheumatoid
Arthritis
Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune
disease characterized by inflammation in the lining of joints (or
synovium), causing joint damage with chronic pain, stiffness, and
swelling.4-5 RA causes limited range of motion and decreased joint
function.4-5 The condition is more common in women than in men, who
account for 75% of patients diagnosed with RA.4-5
About Orencia
Orencia is indicated for reducing signs and symptoms, inducing
major clinical response, inhibiting the progression of structural
damage, and improving physical function in adult patients with
moderately to severely active rheumatoid arthritis. Orencia may be
used as monotherapy or concomitantly with disease-modifying
antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF)
antagonists.
Orencia is indicated for reducing signs and symptoms in patients
2 years of age and older with moderately to severely active
polyarticular juvenile idiopathic arthritis. Orencia may be used as
monotherapy or concomitantly with methotrexate (MTX).
Orencia should not be administered concomitantly with TNF
antagonists. Orencia is not recommended for use concomitantly with
other biologic rheumatoid arthritis (RA) therapy, such as
anakinra.
Orencia is intended for use under the guidance of a physician or
healthcare practitioner.
Indications/Usage and Important Safety Information for
ORENCIA® (abatacept)
Indication and Usage
Adult Rheumatoid Arthritis (RA): ORENCIA® (abatacept) is
indicated for reducing signs and symptoms, inducing major clinical
response, inhibiting the progression of structural damage, and
improving physical function in adult patients with moderately to
severely active RA. ORENCIA may be used as monotherapy or
concomitantly with disease-modifying, anti-rheumatic drugs (DMARDs)
other than tumor necrosis factor (TNF) antagonists.
Juvenile Idiopathic Arthritis (JIA): ORENCIA® (abatacept)
is indicated for reducing signs and symptoms in patients aged 2
years of age and older with moderately to severely active
polyarticular JIA. ORENCIA may be used as monotherapy or
concomitantly with methotrexate (MTX).
Important Limitations of Use: ORENCIA should not be
administered concomitantly with TNF antagonists, and is not
recommended for use concomitantly with other biologic RA therapy,
such as anakinra.
Important Safety Information for
ORENCIA®
(abatacept)
Concomitant Use with TNF Antagonists: Concurrent therapy
with ORENCIA and a TNF antagonist is not recommended. In controlled
clinical trials, adult patients receiving concomitant intravenous
ORENCIA and TNF antagonist therapy experienced more infections
(63%) and serious infections (4.4%) compared to patients treated
with only TNF antagonists (43% and 0.8%, respectively), without an
important enhancement of efficacy.
Hypersensitivity: Anaphylaxis or anaphylactoid reactions
can occur during or after an infusion and can be life-threatening.
There were 2 cases (<0.1%; n=2688) of anaphylaxis or
anaphylactoid reactions in clinical trials with adult RA patients
treated with intravenous ORENCIA. Other reactions potentially
associated with drug hypersensitivity, such as hypotension,
urticaria, and dyspnea, each occurred in <0.9% of patients.
There was one case of a hypersensitivity reaction with ORENCIA in
JIA clinical trials (0.5%; n=190). In postmarketing experience, a
case of fatal anaphylaxis following the first infusion of ORENCIA
was reported. Appropriate medical support measures for treating
hypersensitivity reactions should be available for immediate use.
If an anaphylactic or other serious allergic reaction occurs,
administration of ORENCIA should be stopped immediately and
permanently discontinued, with appropriate therapy instituted.
Infections: Serious infections, including sepsis and
pneumonia, have been reported in patients receiving ORENCIA. Some
of these infections have been fatal. Many of the serious infections
have occurred in patients on concomitant immunosuppressive therapy
which, in addition to their underlying disease, could further
predispose them to infection. Caution should be exercised in
patients with a history of infection or underlying conditions which
may predispose them to infections. Treatment with ORENCIA should be
discontinued if a patient develops a serious infection. Patients
should be screened for tuberculosis and viral hepatitis in
accordance with published guidelines, and if positive, treated
according to standard medical practice prior to therapy with
ORENCIA.
Immunizations: Live vaccines should not be given
concurrently with ORENCIA or within 3 months of its
discontinuation. The efficacy of vaccination in patients receiving
ORENCIA is not known. ORENCIA may blunt the effectiveness of some
immunizations. It is recommended that JIA patients be brought up to
date with all immunizations in agreement with current immunization
guidelines prior to initiating therapy with ORENCIA.
Use in Patients with Chronic Obstructive Pulmonary Disease
(COPD): Adult COPD patients treated with ORENCIA developed
adverse events more frequently than those treated with placebo (97%
vs 88%, respectively). Respiratory disorders occurred more
frequently in patients treated with ORENCIA compared to those on
placebo (43% vs 24%, respectively), including COPD exacerbation,
cough, rhonchi, and dyspnea. A greater percentage of patients
treated with ORENCIA developed a serious adverse event compared to
those on placebo (27% vs 6%), including COPD exacerbation [3 of 37
patients (8%)] and pneumonia [1 of 37 patients (3%)]. Use of
ORENCIA in patients with RA and COPD should be undertaken with
caution, and such patients monitored for worsening of their
respiratory status.
Blood Glucose Testing: ORENCIA for intravenous
administration contains maltose, which may result in falsely
elevated blood glucose readings on the day of infusion when using
blood glucose monitors with test strips utilizing glucose
dehydrogenase pyrroloquinoline quinone (GDH-PQQ). Consider using
monitors and advising patients to use monitors that do not react
with maltose, such as those based on glucose dehydrogenase nicotine
adenine dinucleotide (GDH-NAD), glucose oxidase or glucose
hexokinase test methods. ORENCIA for subcutaneous (SC)
administration does not contain maltose; therefore, patients do not
need to alter their glucose monitoring.
Pregnancy: There are no adequate and well-controlled
studies of ORENCIA use in pregnant women and the data with ORENCIA
use in pregnant women are insufficient to inform on drug-associated
risk. A pregnancy registry has been established to monitor
pregnancy outcomes in women exposed to ORENCIA during pregnancy.
Healthcare professionals are encouraged to register patients by
calling 1-877-311-8972.
Lactation: There is no information regarding the presence
of abatacept in human milk, the effects on the breastfed infant, or
the effects on milk production. However, abatacept was present in
the milk of lactating rats dosed with abatacept.
Most Serious Adverse Reactions: Serious infections (3%
ORENCIA vs 1.9% placebo) and malignancies (1.3% ORENCIA vs 1.1%
placebo).
Malignancies: The overall frequency of malignancies was
similar between adult patients treated with ORENCIA or placebo.
However, more cases of lung cancer were observed in patients
treated with ORENCIA (0.2%) than those on placebo (0%). A higher
rate of lymphoma was seen compared to the general population;
however, patients with RA, particularly those with highly active
disease, are at a higher risk for the development of lymphoma. The
potential role of ORENCIA in the development of malignancies in
humans is unknown.
Most Frequent Adverse Events (≥10%): Headache, upper
respiratory tract infection, nasopharyngitis, and nausea were the
most commonly reported adverse events in the adult RA clinical
studies. Other events reported in ≥5% of JIA patients were
diarrhea, cough, pyrexia, and abdominal pain. In general, the
adverse events in pediatric patients were similar in frequency and
type to those seen in adult patients.
Note concerning ORENCIA administration options:
Intravenous dosing has not been studied in patients younger than 6
years of age. The safety and efficacy of ORENCIA ClickJect
Autoinjector for subcutaneous injection has not been studied in
patients under 18 years of age.
Please see Full Prescribing Information at
http://packageinserts.bms.com/pi/pi_orencia.pdf.
ORENCIA® (abatacept) is a registered trademark of
Bristol-Myers Squibb Company.
About Bristol-Myers Squibb
Immunoscience
With a robust pipeline of immunomodulatory therapies,
Bristol-Myers Squibb is committed to the discovery and development
of transformational medicines that could lead to long-term
remission in patients with autoimmune diseases. As we discover more
about the immune system in such diseases with substantial unmet
medical needs, the potential for developing novel therapies that
target specific pathways in the immune system continues to drive
our research efforts.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2016 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
*Abatacept study to Gauge Remission and
joint damage progression in MTX-naive patients with Early
Erosive RA
**Assessing Very Early Rheumatoid
Arthritis Treatment
***Abatacept versus AdaliMumab ComParison
in BioLogic-NaivE RA Subjects with Background
Methotrexate
References
1. Fleischmann R., Weinblatt M., Ahmad H., et al. Efficacy of
Abatacept Versus Adalimumab in Patients with Serepositive, Erosive
Early RA: Analysis of a Randomized Controlled Clinical Trial
(AMPLE). EULAR 2017 Abstract.
2. Jansen D., Emery P., Smolen J, et al. Association Between
Conversation to ACPA/RD Serenegative Status and Clinical Outcomes
Following Treatment with Abatacept in Combination with Methotrexate
Compared with Methtrexate Alone in Patients with Early Rheumatoid
Arthritis and Poor Prognostic Indicator. EULAR 2017 Abstract.
3. Ahmad H., Baker J., Emery P., et al. Evaluation of the Impact
of Baseline Levels of MRI-Detected Inflammation of Treatment
Response in Early, Seropositive, MTX-Naïve RA: Data from AVERT
Trial. EULAR 2017 Abstract.
4. American College of Rheumatology. Rheumatoid Arthritis.
https://www.rheumatology.org/i-am-a/patient-caregiver/diseases-conditions/rheumatoid-arthritis.
Accessed May 11, 2017.
5. Centers for Disease Control and Prevention. Rheumatoid
Arthritis Fact Sheet.
https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html.
Accessed May 11, 2017
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170614005142/en/
Bristol-Myers Squibb CompanyMedia:Robert Perry,
407-492-4616rob.perry@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024